Clinical Trial Update: A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy [Phase 2]

View source ↗

Summary

This clinical trial update reports results from a Phase 2 study of risdiplam in infants who are genetically diagnosed and presymptomatic for spinal muscular atr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• Risdiplam (Evrysdi) (risdiplam)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Muscular Atrophy, Spinal | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-03-05